BR112022016873A2 - Combinação, kit, e, tasquinimod ou um sal farmaceuticamente aceitável do mesmo para uso no tratamento de mieloma múltiplo - Google Patents
Combinação, kit, e, tasquinimod ou um sal farmaceuticamente aceitável do mesmo para uso no tratamento de mieloma múltiploInfo
- Publication number
- BR112022016873A2 BR112022016873A2 BR112022016873A BR112022016873A BR112022016873A2 BR 112022016873 A2 BR112022016873 A2 BR 112022016873A2 BR 112022016873 A BR112022016873 A BR 112022016873A BR 112022016873 A BR112022016873 A BR 112022016873A BR 112022016873 A2 BR112022016873 A2 BR 112022016873A2
- Authority
- BR
- Brazil
- Prior art keywords
- tasquinimod
- combination
- multiple myeloma
- treatment
- kit
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
COMBINAÇÃO, KIT, E, TASQUINIMOD OU UM SAL FARMACEUTICAMENTE ACEITÁVEL DO MESMO PARA USO NO TRATAMENTO DE MIELOMA MÚLTIPLO. Uma combinação compreendendo tasquinimod, ou um sal farmaceuticamente aceitável do mesmo, e pelo menos um composto adicional selecionado a partir de um inibidor de proteassoma, uma imida imunomoduladora e um anticorpo, para uso no tratamento de mieloma múltiplo. Um kit compreendendo tasquinimod e uma bula com instruções para usar tasquinimod em combinação com pelo menos um composto adicional selecionado a partir de um inibidor de proteassoma, uma imida imunomoduladora e um anticorpo, para tratar mieloma múltiplo em um indivíduo. Tasquinimod para uso no tratamento de mieloma múltiplo, em combinação com um composto adicional selecionado a partir de um inibidor de proteassoma, uma imida imunomoduladora e um anticorpo.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062984474P | 2020-03-03 | 2020-03-03 | |
EP20160815 | 2020-03-03 | ||
US202163148522P | 2021-02-11 | 2021-02-11 | |
PCT/EP2021/055337 WO2021175924A1 (en) | 2020-03-03 | 2021-03-03 | Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022016873A2 true BR112022016873A2 (pt) | 2022-10-25 |
Family
ID=74797955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022016873A BR112022016873A2 (pt) | 2020-03-03 | 2021-03-03 | Combinação, kit, e, tasquinimod ou um sal farmaceuticamente aceitável do mesmo para uso no tratamento de mieloma múltiplo |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230085883A1 (pt) |
EP (1) | EP4114368A1 (pt) |
JP (1) | JP2023519153A (pt) |
KR (1) | KR20220149579A (pt) |
CN (1) | CN115209881A (pt) |
AU (1) | AU2021229611A1 (pt) |
BR (1) | BR112022016873A2 (pt) |
CA (1) | CA3168070A1 (pt) |
IL (1) | IL295780A (pt) |
MX (1) | MX2022010327A (pt) |
WO (1) | WO2021175924A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114848826B (zh) * | 2022-07-06 | 2023-03-28 | 北京天宇恒泰科技有限公司 | 用于治疗胰腺癌的组合物及用途和评价系统 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
EP0690452A3 (en) | 1994-06-28 | 1999-01-07 | Advanced Micro Devices, Inc. | Electrically erasable memory and method of erasure |
SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
SE0002320D0 (sv) | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
JP5881691B2 (ja) | 2010-07-09 | 2016-03-09 | アクティブ バイオテック エイビー | キノリン−3−カルボキサミドの製造方法 |
EP2537517A1 (en) | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
CN107108510B (zh) | 2014-09-23 | 2020-10-23 | 活跃生物技术有限公司 | 用于治疗多发性骨髓瘤的喹啉甲酰胺 |
AU2015340359B2 (en) * | 2014-10-30 | 2019-11-21 | Big Dna Ltd | Combination therapy |
EP3180005B1 (en) | 2014-11-19 | 2017-12-27 | Active Biotech AB | Quinoline carboxamides for use in the treatment of leukemia |
EP3067062A1 (en) * | 2015-03-13 | 2016-09-14 | Ipsen Pharma S.A.S. | Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament |
WO2018075807A1 (en) * | 2016-10-19 | 2018-04-26 | California Institute For Biomedical Research | Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof |
-
2021
- 2021-03-03 CN CN202180018465.8A patent/CN115209881A/zh active Pending
- 2021-03-03 JP JP2022553036A patent/JP2023519153A/ja active Pending
- 2021-03-03 KR KR1020227034006A patent/KR20220149579A/ko unknown
- 2021-03-03 WO PCT/EP2021/055337 patent/WO2021175924A1/en unknown
- 2021-03-03 EP EP21708660.2A patent/EP4114368A1/en active Pending
- 2021-03-03 IL IL295780A patent/IL295780A/en unknown
- 2021-03-03 CA CA3168070A patent/CA3168070A1/en active Pending
- 2021-03-03 BR BR112022016873A patent/BR112022016873A2/pt unknown
- 2021-03-03 MX MX2022010327A patent/MX2022010327A/es unknown
- 2021-03-03 US US17/802,124 patent/US20230085883A1/en active Pending
- 2021-03-03 AU AU2021229611A patent/AU2021229611A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL295780A (en) | 2022-10-01 |
KR20220149579A (ko) | 2022-11-08 |
JP2023519153A (ja) | 2023-05-10 |
MX2022010327A (es) | 2022-11-09 |
CN115209881A (zh) | 2022-10-18 |
CA3168070A1 (en) | 2021-09-10 |
AU2021229611A1 (en) | 2022-10-27 |
EP4114368A1 (en) | 2023-01-11 |
US20230085883A1 (en) | 2023-03-23 |
WO2021175924A1 (en) | 2021-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023002195A (es) | Compuestos y metodos para el tratamiento de infecciones virales. | |
EA200800006A1 (ru) | Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i | |
MA54327B1 (fr) | Inhibiteurs de kras g12c | |
EA201391705A1 (ru) | Триазолпиридиновые ингибиторы 11-бета-гидроксистероиддегидрогеназы типа i | |
EA200601766A1 (ru) | Производные имидазола | |
CY1109295T1 (el) | Μεθοδοι για την αντιμετωπιση της νοσου παρκινσον | |
BRPI0508254A (pt) | métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos | |
EA200900802A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
NO20054195D0 (no) | Isoksazolforbindelser som inhibitorer for varmesjokkproteiner | |
EA200802329A1 (ru) | Производные триазола ii | |
UY26380A1 (es) | Inhibidores de fab i | |
TR201900306T4 (tr) | Mek inhibitörlerini kullanma yöntemleri. | |
MX2014000518A (es) | Inhibidores de la tirosina quinasa de bruton. | |
EA200600078A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
EA200900344A1 (ru) | Циклические ингибиторы 11-бета-гидроксистероиддегидрогеназы типа i | |
EA201000098A1 (ru) | Производные хиназолинамида | |
BR112015026021A2 (pt) | terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer | |
CL2008001782A1 (es) | Uso de una composicion que comprende un compuesto derivado de heterociclo para tratar o prevenir la perdida de flujo intestinal; composicion que comprende dicho compusto; y kit que comprende la composicion. | |
EA200801413A1 (ru) | Гетероциклические сетр ингибиторы | |
DK1429756T3 (da) | Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer | |
RU2009149684A (ru) | Комбинации вазоактивных веществ с эстрогенами и их применение для лечения сексуальных дисфункций у женщин | |
CR20230100A (es) | Compuestos fosfolípidos y usos de los mismos | |
BR112022016873A2 (pt) | Combinação, kit, e, tasquinimod ou um sal farmaceuticamente aceitável do mesmo para uso no tratamento de mieloma múltiplo | |
CO2022000266A2 (es) | Inhibidores de enzimas | |
CR20210143A (es) | Utilización de un inhibidor de catepsina s contra la formación de anticuerpos anti-fármaco |